FDA Approves Gedatolisib for ER+/HER2- Breast Cancer Treatment

The FDA has approved gedatolisib, a kinase inhibitor, for treating ER+/HER2- locally advanced or metastatic breast cancer. This approval follows positive results from the VIKTORIA-1 trial, which showed the drug improved progression-free survival while limiting side effects. This offers a new therapeutic option for patients by targeting a key signaling pathway in tumor growth.